Start here if you're new
what it is
It develops drugs for lung and brain diseases tied to faulty kinase signals.
how it gets paid
Last year Inhikibase Therap made $0 in revenue.
what just happened
Revenue was $0 and EPS was -$0.40, which is what a pre-revenue biotech looks like when the bill comes due.
At a glance
B balance sheet — gets the job done, barely
65/100 earnings predictability — reasonably predictable
-$1.16 fy2024 eps est
$0M fy2023 rev est
1.5 beta
xvary composite: 49/100 — below average
What they do
It develops drugs for lung and brain diseases tied to faulty kinase signals.
You are buying a science lab, not a business. It has 15 employees and $0 revenue, so the moat is data, not sales. If IKT-001 works, about 50,000 Americans sit in the target pool, and every result matters more than the logo.
How they make money
$0
annual revenue
The products that matter
treats Parkinson's disease
IkT-148009
$0M revenue · Phase 2
it's the entire near-term thesis: one Phase 2 Parkinson's asset, zero commercial revenue, and a readout timeline that stretches into 2026–2027.
sole lead asset
supports future programs
Preclinical Pipeline
$0M revenue · pre-human
these programs add optionality, but they are still preclinical. right now, $0M revenue means you are not paying for proven pipeline depth.
early option value
Key numbers
$0
annual revenue
No sales means you are buying trial data, not a customer list.
$100.0M
recent raise
The cash buys time, but the share count also grows.
50,000
PAH patients
A tiny pool means one approval matters more than a big market story.
15
employees
A 15-person shop cannot absorb many misses.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for IKT right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue was $0 and EPS was -$0.40, which is what a pre-revenue biotech looks like when the bill comes due.
EDGAR shows $0 revenue in the latest quarter. EPS was -$0.40, which matches a company still paying for trials instead of collecting sales.
$0
revenue
$0.40
eps
n/a
n/a
the number that mattered
$0 revenue matters because it means the stock lives on clinical news, not sales.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is Phase 2 failure or weak efficacy for IkT-148009 in Parkinson's disease.
med
IkT-148009 is the whole near-term equity story
The company describes one lead clinical asset in Phase 2. If that trial misses, the market loses the main reason to ascribe a $242M value to a business with $0 revenue.
This is a binary setup: one failed readout can break the thesis in a single day.
med
Cash runway is an asset until it becomes a deadline
The company has $77.32M in cash and no product revenue. If trial timing slips or spending runs hotter than planned, financing risk moves from background noise to the main event.
With $0M coming in, any capital raise is funded by shareholders or new investors — usually not at the old terms.
med
Thin operating base means volatility stays high
Price stability is 5 / 100 and beta is 1.5. That combination usually means sentiment can overpower fundamentals, especially when fundamentals are still mostly clinical updates and cash balances.
You can be right on the science and still sit through painful swings before the market agrees.
one asset, $0 revenue, and $77.32M in cash means the same risk hits both the science and the financing at once.
source: institutional data · regulatory filings · risk analysis
Pay attention to
clinical clock
the 2026–2027 Phase 2 readout window
That is the event the whole page points toward. For a $242M pre-revenue biotech, time to data is time to truth.
cash
whether $77.32M lasts long enough
Cash is the real operating metric here. If runway shortens before the key trial update, dilution risk moves up the stack fast.
sentiment
volatility staying disconnected from fundamentals
A 5 / 100 price stability score and 1.5 beta tell you this stock can move on mood as much as on news.
thesis risk
signs the story is becoming more than one asset
Right now there is no diversification benefit. Until another program matters, all roads still lead back to IkT-148009.
Analyst rankings
earnings predictability
65 / 100
Losses are easier to model than drug approvals. In human-speak: analysts can sketch the cash burn better than the end market.
analyst coverage
7 analysts
Six publish estimates and the median target is $5.00. That tells you coverage exists, not that consensus is certainty.
source: institutional data
Institutional activity
institutional ownership data for IKT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive